Tumor suppressor p53 but not cGMP mediates NO-induced expression of p21(Waf1/Cip1/Sdi1) in vascular smooth muscle cells

Molecular Pharmacology

Volumn 56, Issue 5, 1999, Pages 938-946

  Ishida, Akio ^c   Sasaguri, Toshiyuki ^b   Miwa, Yoshikazu ^c   Kosaka, Chiya ^a   Taba, Yoji ^c   Abumiya, Takeo ^c  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIN DEPENDENT KINASE INHIBITOR; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; PROTEIN P21; PROTEIN P53;

ARTICLE; CELL PROLIFERATION; DNA BINDING; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0032756587     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.5.938     Document Type: Article

References (38)

1. Abell TJ, Richards AM, Ikram H, Espiner EA and Yandle T (1989) Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor. Biochem Biophys Res Commun 160:1392-1396.
2. Agarwal ML, Taylor WR, Chernov MV, Chernova OB and Stark GR (1998) The p53 network. J Biol Chem 273:1-4.
3. Ambs S, Hussain SP and Harris CC (1997) Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 11:443-448.
4. 2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochem J 288:527-532.
5. Buttery LDK, Springall DR, Chester AH, Evans TJ, Standfield N, Parums DV, Yacoub MH and Polak JM (1996) Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 75:77-85.
6. Calmels S, Hainaut P and Ohshima H (1997) Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res 57:3365-3369.
7. Chiche JD, Schlutsmeyer SM, Bloch DB, de la Monte SM, Roberts JD Jr, Filippov G, Janssens SP, Rosenzweig A and Bloch KD (1998) Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem 273:34263-34271.
8. Cho Y, Gorina S, Jeffrey PD and Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (Wash DC) 265:346-355.
9. Cornwell TL, Arnold E, Boerth NJ and Lincoln TM (1994) Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 267:C1405-C1413.
10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
11. Esaki T, Hayashi T, Muto E, Yamada K, Kuzuya M and Iguchi A (1997) Expression of inducible nitric oxide synthase in T lymphocytes and macrophages of cholesterol-fed rabbits. Atherosclerosis 128:39-46.
12. Estrada C, Gómez C, Martín-Nieto J, De Frutos T, Jiménez A and Villalobo A (1997) Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase. Biochem J 326:369-376.
13. Forrester K, Arabs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR and Harris CC (1996) Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 93:2442-2447.
14. Furuya M, Yoshida M, Hayashi Y, Ohnuma N, Minamino N, Kangawa K and Matsuo H (1991) C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochem Biophys Res Commun 177:927-931.
15. Garg UC and Hassid A (1989) Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 83:1774-1777.
16. Garg UC and Hassid A (1990) Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/c 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem Biophys Res Commun 171:474-479.
17. Cartel AL, Serfas MS and Tyner AL (1996) p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213:138-149.
18. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K and Mayer B (1995) Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one. Mol Pharmacol 48:184-188.
19. Guevara NV, Kim HS, Antonova EI and Chan L (1999) The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med 5:335-339.
20. Ho YS, Wang YJ and Lin JK (1996) Induction and p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol Carcinog 16:20-31.
21. sdi1/Cip1/Waf1 by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem 272:10050-10057.
22. Kariya K, Kawahara Y, Araki S, Fukuzaki H and Takai Y (1989) Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis 80:143-147.
23. Lander HM (1997) An essential role for free radicals and derived species in signal transduction. FASEB J 11:118-124.
24. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10:934-947.
25. Luoma JS, Strålin P, Marklund SL, Hiltunen TP, Särkioja T and Ylä-Herttuala S (1998) Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol 18:157-167.
26. McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ and Akers DL (1993) L-Arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 193:291-296.
27. Meßmer UK, Ankarcrona M, Nicotera P and Brüne B (1994) p53 expression in nitric oxide-induced apoptosis. FEBS Lett 355:23-26.
28. Murad F (1986) Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 78:1-5.
29. Ohmi K, Masuda T, Yamaguchi H, Sakurai T, Kudo Y, Katsuki M and Nonomura Y (1997) A novel aortic smooth muscle cell line obtained from p53 knock out mice expresses several differentiation characteristics. Biochem Biophys Res Commun 238:154-158.
30. WAF1 regulates neuronal differentiation of PC12 cells. J Biol Chem 272:24002-24007.
31. Rainwater R, Parks D, Anderson ME, Tegtmeyer P and Mann K (1995) Role of cystein residues in regulation of p53 function. Mol Cell Biol 15:3892-3903.
32. Roy B, Lepoivre M, Henry Y and Fontecave M (1995) Inhibition of ribonucleotide reductase by nitric oxide derived from thionitrites: Reversible modifications of both subunits. Biochemistry 34:5411-5418.
33. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS and Sessa WC (1998) Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 101:731-736.
34. Shears LL 2nd, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, Watkins SC and Tzeng E (1998) Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg 187:295-306.
35. Tarry WC and Makhoul RG (1994) L-Arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscler Thromb 14:938-943.
36. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP and Dzau VJ (1995) Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 92:1137-1141.
37. Walter U (1989) Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system. Rev Physiol Biochem Pharmacol 113:41-88.
38. Yu SM, Hung LM and Lin CC (1997) cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 95:1269-1277.